Follow The Filings

AXSM Axsome Therapeutics Inc.

Health Care, filed as AXSOME THERAPEUTICS INC (COM), Equity As of 2026 Q3 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 1

  • 1 Owner
  • Max 0.4%
  • $2.7M
  • 1 reduce

In 2026 Q3 Torray Investment Partners trimmed Axsome Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 0.4% (Torray Investment Partners). Not free-float ownership.

  1. Torray Investment Partners Reduce 0.36%

Who owns AXSM

Sorted by value, long equity only, as of 2026 Q3.

History
Torray Investment Partners 0.36%, was 0.49% Reduce −0.3% 14,887 $2.7M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by AXSM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AXSM insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $134M sold by 6 insiders under 10b5-1 plans
  1. Mark L. Jacobson COO
    Planned sale
    $2.1M 10,000 shares at $208.65 100% of stake
    Traded Sep 3 Filed Sep 3
    ↗
  2. Herriot Tabuteau CEO
    Planned sale
    $10.5M 49,664 shares at $212.19 87% of stake
    Traded Aug 5–6 Filed Aug 7
    ↗
  3. Herriot Tabuteau CEO
    Planned sale
    $11.9M 49,666 shares at $240.25 87% of stake
    Traded Jul 1 Filed Jul 1
    ↗
  4. Herriot Tabuteau CEO
    Planned sale
    $12M 49,670 shares at $241.01 87% of stake
    Traded Jun 9 Filed Jun 9
    ↗
  5. Nick Pizzie CFO
    Planned sale
    $7.9M 33,000 shares at $240.09 44% of stake
    Traded Jun 9 Filed Jun 9
    ↗
  6. Mark Coleman Director
    Planned sale
    $4M 17,537 shares at $229.20 37% of stake
    Traded May 29–Jun 2 Filed Jun 2
    ↗
  7. Mark L. Jacobson COO
    Planned sale
    $1.1M 4,750 shares at $227.95 100% of stake
    Traded May 4–5 Filed May 5
    ↗
  8. Ari Maizel Chief Commercial Officer
    Planned sale
    $1.4M 7,500 shares at $182.42 100% of stake
    Traded Apr 22 Filed Apr 23
    ↗
  9. Mark Coleman Director
    Planned sale
    $4M 25,000 shares at $161.11 35% of stake
    Traded Feb 26 Filed Feb 27
    ↗
  10. Mark L. Jacobson COO
    Planned sale
    $5.7M 35,378 shares at $161.88 100% of stake
    Traded Feb 26 Filed Feb 27
    ↗
  11. Herriot Tabuteau CEO
    Planned sale
    $6M 32,410 shares at $185.60 82% of stake
    Traded Feb 2 Filed Feb 2
    ↗
  12. Nick Pizzie CFO
    Planned sale
    $2.3M 12,000 shares at $187.92 22% of stake
    Traded Jan 22 Filed Jan 23
    ↗
  13. Ari Maizel Chief Commercial Officer
    Planned sale
    $1.4M 7,500 shares at $184.44 100% of stake
    Traded Jan 21 Filed Jan 23
    ↗
  14. Herriot Tabuteau CEO
    Planned sale
    $23.9M 139,414 shares at $171.30 95% of stake
    Traded Jan 5–7 Filed Jan 7
    ↗
  15. Mark E Saad Director
    Planned sale
    $6.2M 37,577 shares at $165.18 79% of stake
    Traded Dec 31, 2025 Filed Jan 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 31 option exercises and 5 sales to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 13 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $270.6M $385.69M $638.5M
Net income -$239.24M -$287.22M -$183.17M
Net margin * -88.4% -74.5% -28.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $504.26M $485.06M $588.99M
Total non-current assets * $83.97M $83.43M $100.82M
Total assets $588.24M $568.5M $689.8M
Total current liabilities $138.85M $230.1M $378.84M
Total non-current liabilities * $258.4M $281.38M $222.67M
Total equity $190.98M $57.02M $88.3M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$145.08M -$128.41M -$93.4M
Cash from investing -$582,000 -$270,000 -$480,000
Cash from financing $331.01M $57.84M $101.46M
Net change in cash $185.35M -$70.84M $7.58M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.